Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 5
2014 4
2015 12
2016 6
2017 11
2018 9
2019 15
2020 15
2021 19
2022 16
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Citations

7 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
Avancini A, Sartori G, Gkountakos A, Casali M, Trestini I, Tregnago D, Bria E, Jones LW, Milella M, Lanza M, Pilotto S. Avancini A, et al. Among authors: pilotto s. Oncologist. 2020 Mar;25(3):e555-e569. doi: 10.1634/theoncologist.2019-0463. Epub 2019 Nov 26. Oncologist. 2020. PMID: 32162811 Free PMC article. Review.
Lung cancer remains the leading cause of cancer-related death worldwide. ...To date, the potential impact of physical activity and exercise in lung cancer remains to be fully appreciated, and no specific exercise guidelines for patients with …
Lung cancer remains the leading cause of cancer-related death worldwide. ...To date, the potential impact of physical a …
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
Belluomini L, Avancini A, Sposito M, Milella M, Rossi A, Pilotto S. Belluomini L, et al. Among authors: pilotto s. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1077-1087. doi: 10.1080/14712598.2023.2198087. Epub 2023 Apr 3. Expert Opin Biol Ther. 2023. PMID: 36995069 Review.
EXPERT OPINION: Anti-TROP-2 ADCs represent an innovative upcoming weapon against both non-small cell lung cancer and small cell lung cancer subtypes, pending the results of several ongoing trials. The proper combination and placement of this agent thro …
EXPERT OPINION: Anti-TROP-2 ADCs represent an innovative upcoming weapon against both non-small cell lung cancer and small cel …
Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
Belluomini L, Caldart A, Avancini A, Dodi A, Trestini I, Kadrija D, Sposito M, Tregnago D, Casali M, Riva ST, Sartori G, Menis J, Milella M, Pilotto S. Belluomini L, et al. Among authors: pilotto s. Int J Mol Sci. 2020 Dec 22;22(1):42. doi: 10.3390/ijms22010042. Int J Mol Sci. 2020. PMID: 33375194 Free PMC article. Review.
Infectious diseases represent a relevant issue in lung cancer patients. Bacterial and viral infections might influence the patients' prognosis, both directly affecting the immune system and indirectly impairing the outcome of anticancer treatments, mainly immunother …
Infectious diseases represent a relevant issue in lung cancer patients. Bacterial and viral infections might influence the pat …
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Ferrara MG, Di Noia V, D'Argento E, Vita E, Damiano P, Cannella A, Ribelli M, Pilotto S, Milella M, Tortora G, Bria E. Ferrara MG, et al. Among authors: pilotto s. Cancers (Basel). 2020 May 8;12(5):1196. doi: 10.3390/cancers12051196. Cancers (Basel). 2020. PMID: 32397295 Free PMC article. Review.
Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of patients, despite platinum-based combination chemotherapy, the majority of patients affected by non-small-cell lung cancer (NSCLC) did not live longer than one year. With deepe …
Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of patients, despite platinum-based combination chemo …
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.
Carbone C, Piro G, Di Noia V, D'Argento E, Vita E, Ferrara MG, Pilotto S, Milella M, Cammarota G, Gasbarrini A, Tortora G, Bria E. Carbone C, et al. Among authors: pilotto s. Mediators Inflamm. 2019 Nov 11;2019:7652014. doi: 10.1155/2019/7652014. eCollection 2019. Mediators Inflamm. 2019. PMID: 31827379 Free PMC article. Review.
Lung cancer is one of the deadliest and most common malignancies in the world, representing one of the greatest challenges in cancer treatment. ...In this review, we discuss some of the major findings depicting bacteria as crucial gatekeeper for the immune re …
Lung cancer is one of the deadliest and most common malignancies in the world, representing one of the greatest challenges in …
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around.
Gkountakos A, Sartori G, Falcone I, Piro G, Ciuffreda L, Carbone C, Tortora G, Scarpa A, Bria E, Milella M, Rosell R, Corbo V, Pilotto S. Gkountakos A, et al. Among authors: pilotto s. Cancers (Basel). 2019 Aug 9;11(8):1141. doi: 10.3390/cancers11081141. Cancers (Basel). 2019. PMID: 31404976 Free PMC article. Review.
Lung cancer is the most common malignancy and cause of cancer deaths worldwide, owing to the dismal prognosis for most affected patients. ...PTEN protein loss is a frequent event in lung cancer, but genetic alterations are not equally detected. …
Lung cancer is the most common malignancy and cause of cancer deaths worldwide, owing to the dismal prognosis for most …
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives.
Sartori G, Belluomini L, Lombardo F, Avancini A, Trestini I, Vita E, Tregnago D, Menis J, Bria E, Milella M, Pilotto S. Sartori G, et al. Among authors: pilotto s. Expert Rev Anticancer Ther. 2020 Jul;20(7):531-542. doi: 10.1080/14737140.2020.1776119. Epub 2020 Jun 12. Expert Rev Anticancer Ther. 2020. PMID: 32529917 Review.
INTRODUCTION: Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, acting as an irreversible and multitarget blocker of ErbB family members. Afatinib is currently approved for advanced non-small-cell lung cancer (NSCLC) …
INTRODUCTION: Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, acting as an irreversible a …
Cellular and molecular biology of small cell lung cancer: an overview.
Karachaliou N, Pilotto S, Lazzari C, Bria E, de Marinis F, Rosell R. Karachaliou N, et al. Among authors: pilotto s. Transl Lung Cancer Res. 2016 Feb;5(1):2-15. doi: 10.3978/j.issn.2218-6751.2016.01.02. Transl Lung Cancer Res. 2016. PMID: 26958489 Free PMC article. Review.
Although the incidence of small cell lung cancer (SCLC) has declined during the past 30 years, it remains a frustrating disease to research and treat. ...
Although the incidence of small cell lung cancer (SCLC) has declined during the past 30 years, it remains a frustrating diseas …
Tubulin inhibitors in non-small cell lung cancer: looking back and forward.
Ferrara R, Pilotto S, Peretti U, Caccese M, Kinspergher S, Carbognin L, Karachaliou N, Rosell R, Tortora G, Bria E. Ferrara R, et al. Among authors: pilotto s. Expert Opin Pharmacother. 2016 Jun;17(8):1113-29. doi: 10.1517/14656566.2016.1157581. Epub 2016 Mar 10. Expert Opin Pharmacother. 2016. PMID: 26898217 Review.
INTRODUCTION: Although the advent of target therapy for lung cancer has brought about outstanding results, this benefit is confined to a subgroup of molecularly selected patients, whereas for most non-small cell lung cancer (NSCLC) patients, chemothera …
INTRODUCTION: Although the advent of target therapy for lung cancer has brought about outstanding results, this benefit is con …
Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
Belluomini L, Avancini A, Pasqualin L, Insolda J, Sposito M, Menis J, Tregnago D, Trestini I, Ferrara MG, Bria E, Milella M, Pilotto S. Belluomini L, et al. Among authors: pilotto s. Expert Rev Anticancer Ther. 2022 Aug;22(8):785-794. doi: 10.1080/14737140.2022.2093190. Epub 2022 Jun 27. Expert Rev Anticancer Ther. 2022. PMID: 35726802 Review.
Rearranged during transfection (RET) gene is a validated target in non-small-cell lung cancer (NSCLC). Selpercatinib is currently approved for adult patients with metastatic RET fusion-positive NSCLC. ...
Rearranged during transfection (RET) gene is a validated target in non-small-cell lung cancer (NSCLC). Selpercatinib is curren …
115 results